News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Topigen Pharmaceuticals Inc. Completes Enrollment of Phase II Clinical Study of TPI ASM8 in Asthma


7/23/2008 8:25:59 AM

MONTREAL--(Marketwire - July 23, 2008) - TOPIGEN Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced the completion of patient enrollment in a Phase II safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. The current clinical study builds on prior efficacy and safety data in a three-day study of TPI ASM8 in an allergen challenge model. TPI ASM8 is a novel, inhaled, anti-inflammatory drug in development for the management of moderate or severe asthma.

Read at BioSpace.com

comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES